Other
Hepatic Fibrosis
6
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Hepatic fibrosis is an early-stage landscape with 6 programs across 4 companies. The most active players are Bristol-Myers Squibb, Beijing Continent Pharmaceutical Co, Ltd., Horizon Therapeutics Ireland DAC. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Not yet recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Completed·—·N/A·NCT03884062·3,000 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)